Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Operating Expenses (2022 - 2026)

Axsome Therapeutics' Operating Expenses history spans 5 years, with the latest figure at $254.6 million for Q1 2026.

  • On a quarterly basis, Operating Expenses rose 42.65% to $254.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $881.4 million, a 25.48% increase, with the full-year FY2025 number at $805.3 million, up 20.86% from a year prior.
  • Operating Expenses hit $254.6 million in Q1 2026 for Axsome Therapeutics, up from $223.0 million in the prior quarter.
  • Over the last five years, Operating Expenses for AXSM hit a ceiling of $254.6 million in Q1 2026 and a floor of $38.3 million in Q1 2022.
  • Historically, Operating Expenses has averaged $144.6 million across 5 years, with a median of $165.2 million in 2024.
  • Biggest five-year swings in Operating Expenses: skyrocketed 163.65% in 2023 and later rose 12.71% in 2024.
  • Tracing AXSM's Operating Expenses over 5 years: stood at $84.3 million in 2022, then surged by 101.45% to $169.8 million in 2023, then increased by 12.71% to $191.4 million in 2024, then grew by 16.5% to $223.0 million in 2025, then grew by 14.17% to $254.6 million in 2026.
  • Business Quant data shows Operating Expenses for AXSM at $254.6 million in Q1 2026, $223.0 million in Q4 2025, and $217.1 million in Q3 2025.